Yanira Arce-Ayala
Internal Medicine · San Juan, PRNPI 1619312915
Payments from drug & device makers
Across 184 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst US Sales Co., LLC$737
- Takeda Pharmaceuticals U.S.A., Inc.$642
- PBG Puerto Rico LLC$580
- AbbVie$530
- Sanofi$381
- AstraZeneca$364
- plus $952 from 10 others
What the payments were for
- Food & beverage$4,16199%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst US Sales Co., LLC | 40 | $737 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $642 |
| PBG Puerto Rico LLC | 27 | $580 |
| AbbVie | 20 | $530 |
| Sanofi | 13 | $381 |
| AstraZeneca | 17 | $364 |
| GSK | 9 | $221 |
| Amgen | 6 | $135 |
| Shire North American Group Inc | 2 | $131 |
| Eli Lilly Export S.A. Puerto Rico Branch | 5 | $122 |
| Boehringer Ingelheim | 1 | $108 |
| Sanofi-aventis U.S. LLC | 2 | $86 |
| Genentech USA, Inc. | 4 | $65 |
| Pharming Healthcare, Inc. | 2 | $37 |
| Pfizer | 2 | $26 |
| Blueprint Medicines Corporation | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CINRYZE$125
How this compares
$4,188 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,431 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 33 | $3,256 |
| Fluticasone Propionate | 82 | $1,420 |
| Azelastine Hcl | 39 | $941 |
| Montelukast Sodium | 82 | $643 |
| Mometasone Furoate | 19 | $501 |
| Ipratropium Bromide | 15 | $487 |
| Triamcinolone Acetonide | 33 | $332 |
| Levocetirizine Dihydrochloride | 23 | $212 |
| Hydroxyzine Hcl | 21 | $168 |
| Famotidine | 18 | $93 |
| Prednisone | 27 | $77 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Juan
- Grisell Ortiz LasantaSan Juan$5.9M
- Ricardo FernandezSan Juan$480K
- Pedro del Valle de TomasSan Juan$114K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Roberto Calderon SantiagoSan Juan$20K
- Natalia Almodovar ArbeloSan Juan$9K
- Jeremy FelicianoSan Juan$8K
- Porfirio Diaz-RodriguezSan Juan$8K
- Rafael Figueroa NavarroSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.